Blogs

The MGD patient journey: maintenance over time

Cynthia Matossian, MD, FACS, ABES, continues her discussion on MGD treatment by explaining why it's important for patients to understand that MGD and dry eye are lifelong, chronic conditions requiring regular maintenance and monitoring.

Top 10 stories of 2020 on Ophthalmology Times®

See what ranked most popular in our top 10 stories of 2020.

The MGD patient journey: diagnosis + initial treatment

Cynthia Matossian, MD, FACS, ABES, discusses the big disconnect between signs and symptoms of ocular surface disease, including meibomian gland dysfunction, and why a clear process for educating patients and initiating treatment is essential.

When at first you don’t succeed with MGD patients, keep trying

September 23, 2020

It's not always easy to convince early-stage, minimally symptomatic or symptomatic patients that their MGD should be treated. Cynthia Matossian, MD, FACS, explains why ophthalmologists shouldn't take this personally and how not to accept their denial as a final answer.

As cyclosporine options grow, focus remains on the vehicle

September 10, 2020

Amid a surge in dry eye cases since reopening her practice during the ongoing pandemic, Lisa Nijm, MD, JD, shares how cyclosporine, a well-established form of treatment, poses both challenges and advantages for ophthalmologists.